Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.38 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710290 | 0.91 | NSD2 (0.37) | RXFP1BCAT1NSD2TP53POLB | |
| SCHEMBL6707829 | 0.90 | PLCG2 (0.38) | RXFP1BCAT1NSD2TP53POLB | |
| SCHEMBL6712405 | 0.88 | PLA2G7 (0.35) | RXFP1BCAT1NSD2TP53POLB | |
| SCHEMBL6711741 | 0.85 | HIF1A (0.47) | RXFP1HIF1ANPSR1GPR35NSD2 | |
| SCHEMBL6710188 | 0.84 | GRIK1 (0.40) | RXFP1HIF1ANPSR1GPR35BCAT1 | |
| SCHEMBL6709885 | 0.84 | GPR35 (0.37) | RXFP1HIF1ANPSR1GPR35NSD2 | |
| SCHEMBL6707728 | 0.84 | PABPC1 (0.39) | RXFP1HIF1ANPSR1GPR35POLB | |
| SCHEMBL6709089 | 0.83 | RXFP1 (0.38) | RXFP1HIF1ANPSR1GPR35NSD2 | |
| SCHEMBL6707722 | 0.83 | NSD2 (0.50) | RXFP1HIF1ANPSR1GPR35NSD2 | |
| SCHEMBL6713465 | 0.83 | GPR35 (0.43) | RXFP1HIF1ANPSR1GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | RXFP1 3836/4885HIF1A 296/4885NPSR1 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.